Skip to main content
Springer logoLink to Springer
. 2026 Aug 14;36(10):5222–5232. doi: 10.1007/s11695-026-08894-w

Impact of Bariatric Surgery on Medication Costs and Disease Burden in Obesity: A Retrospective Cohort Study

André Oliveira 1,✉, Carolina Bulhosa 2, Pedro Apolónia 2, Margarida Borges 2,3, Eduardo Lima-da-Costa 1,4, Hugo Santos-Sousa 1,4, Paula Freitas 4,5,6
PMCID: PMC13645855  PMID: 42599584

Abstract

Introduction

Obesity is a highly prevalent chronic disease associated with substantial morbidity, multiple comorbidities, and a significant burden on healthcare systems. Metabolic bariatric surgery (MBS) is effective in achieving weight loss and improving obesity-related comorbidities, potentially reducing pharmacotherapy requirements and overall disease burden. Nevertheless, evidence from Portuguese real-world clinical practice remains limited. Therefore, this study aimed to provide the first Portuguese evaluation of the impact of MBS on pharmacotherapy-related healthcare costs and on the prevalence and burden of obesity-associated comorbidities.

Methods

A retrospective cohort study was conducted. Annual pharmacotherapy costs and changes in the prevalence and burden of obesity-associated comorbidities, measured using Years Lived with Disability (YLD), were compared before and 3 years after surgery.

Results

Three years after MBS, the mean annual pharmacotherapy cost per patient decreased by €56.11 (p < 0.05). Reductions in medication costs were observed for antihypertensive, lipid-lowering, and antidiabetic therapies (all p < 0.05). The prevalence of obesity-related comorbidities also decreased, particularly hypertension, type 2 diabetes mellitus, dyslipidemia and asthma (all p < 0.05). Correspondingly, the estimated burden of disease decreased, with mean YLD declining from 0.022 before surgery to 0.014 3 years after surgery (p < 0.05).

Conclusion

Over 3 years of follow-up, MBS was associated with reductions in medication costs, the prevalence of obesity-related comorbidities, and overall disease burden. These findings highlight the clinical and economic benefits of MBS in the management of obesity and its associated conditions over the medium term.

Key Points

Metabolic bariatric Surgery reduced mean annual pharmacotherapy costs by €56.11 per patient over a 3-year follow-up.

Significant reductions in medication costs were observed for antihypertensive, lipid-lowering, and antidiabetic therapies after metabolic bariatric surgery.

The prevalence of dyslipidemia, hypertension, type 2 diabetes mellitus and asthma decreased by 32%, 21%, 16% and 5%, respectively, three years after surgery.

Mean Years Lived with Disability (YLD) decreased by 36%, from 0.022 preoperatively to 0.014 at 3 years, indicating a substantial reduction in obesity-related disease burden.

Introduction

Obesity is a chronic, complex disease of multifactorial etiology resulting from the interaction of environmental, behavioral, psychological, and genetic factors. It is characterized by an excessive accumulation of body fat that can be detrimental to health [1], and is diagnosed when body mass index (BMI) is equal to or greater than 30 kg/m² [2].

Globally, the prevalence of obesity has more than doubled since 1990, and in 2022, an estimated 43% of the world’s adult population was overweight and 16% was classified as having obesity [1]. In Portugal, 21.8% of the adult population met the criteria for obesity in the same year [3]. Based on these findings and given the substantial burden of disease imposed by obesity through its association with more than 220 comorbidities such as type 2 diabetes mellitus, hypertension, dyslipidemia, asthma, depression, anxiety disorders, and 13 types of cancer, the need for effective treatment and comprehensive management is increasingly evident [4, 5].

The management of obesity is complex, not only because of the need for weight reduction, but also due to the simultaneous treatment of associated comorbidities. In selected cases of grade 1 (i.e., BMI ≥ 30 kg/m²) and in all cases of grade 2 (i.e., BMI ≥ 35 kg/m²) obesity, metabolic bariatric surgery (MBS) is considered the most effective long-term therapeutic option for achieving and maintaining weight loss [6]. Over time, it has become evident that the benefits of these surgeries extend beyond weight reduction, contributing to the improvement or resolution of obesity-related comorbidities and allowing discontinuation or dose reduction of several medications. Indeed, improvements in control of hypertension, type 2 diabetes, and dyslipidemia have been widely documented [7]. Furthermore, MBS has been associated with improvements in asthma and with reductions in the prevalence of the two most common obesity-related psychiatric conditions, namely anxiety and depressive disorders [8–12].

Driven by these benefits, the number of procedures performed worldwide has been steadily increasing. The International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) estimated that approximately 390 000 bariatric procedures were performed globally in 2018 [13], with a continued rise in subsequent years [14].

Despite the growing global and national burden of obesity, the well-documented benefits of MBS in reducing medication needs for comorbidities and the increasing number of procedures performed, evidence from real-world Portuguese settings remains scarce. Although some studies have quantified the economic burden and overall impact of obesity [15], no previous cohorts conducted in Portugal have systematically evaluated prescription patterns or quantified the associated pharmacotherapy costs before and after MBS. This gap is particularly relevant given Portugal’s National Health Service context. The present study addresses this need, providing an assessment of these outcomes in a Portuguese cohort.

Therefore, the primary outcome of this study was to quantify variations in pharmacotherapy-related healthcare costs following MBS, specifically assessing cost reductions associated with the remission or improvement of type 2 diabetes mellitus, hypertension, dyslipidemia, asthma, depression and anxiety disorders. Furthermore, this study aimed to assess the magnitude of the reduction of the prevalence and burden of obesity-associated comorbidities over time using Years Lived with Disability (YLD).

Methods

Study Design and Setting

This retrospective cohort study was conducted at a tertiary referral center for obesity management in Portugal. The cohort was evaluated at two predefined time points: the preoperative assessment and a follow-up medical appointment conducted 3 years after MBS.

Data collection occurred between November and December 2025 using the hospital’s SClínico software.

Participants

A review of medical records between 2021 and 2024 was conducted to identify eligible participants: adult patients (≥ 18 years) who had undergone Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy, or single-anastomosis duodeno-ileal bypass with sleeve gastrectomy and had at least 3 years of postoperative follow-up. Participants were selected from the follow-up appointment three years after surgery, which includes all patients submitted to metabolic surgery with a minimum post-operative follow-up of 3 years. Therefore, the cohort included patients who underwent MBS between 2018 and 2021. Patients who underwent revisional surgery were excluded.

Sampling

The sample size calculation for the paired continuous outcome (costs before vs. after bariatric surgery) was performed using the formula for the paired t-test. Although the final analysis may use non-parametric methods (Wilcoxon test), this approach is recommended because it provides a conservative and widely accepted approximation in the absence of a closed-form formula for the Wilcoxon test. Moreover, the Wilcoxon test has power similar to the t-test for continuous differences, so sample size estimation based on the t-test does not compromise the validity of the analysis.

Due to the absence of robust prior estimates for the standard deviation of cost differences, the sample size was determined based on a standardized effect size. A minimum clinically relevant difference of €1 was considered to correspond to a small-to-moderate effect (Cohen’s d = 0.2). Assuming a two-tailed significance level of 0.05 and a statistical power of 80%, the required sample size was estimated to be of 196 patients.

Variables and Measurements

In this study, to assess the therapeutic regimen of each patient, the national electronic prescribing platform (PEM) was used. This platform allows the identification of the prescribed active substances in the treatment of the obesity-related comorbidities investigated in the present study, before and after MBS (shown in Table 1).

Table 1.

Medications included in the analysis, grouped by disease category, together with the corresponding package price, defined daily dose (DDD), and the estimated daily and annual costs based on the DDD

Molecule Package Price (€) Units/ Package Package Dose DDD Daily price
(€)
Annual price
(€)
Hypertension
Ramipril 8.03 56 2.5 2.5 mg 0.14 52.35
Perindopril 6.71 30 4 4 mg 0.22 81.71
Enalapril 8.55 56 20 10 mg 0.08 27.88
Lisinopril 9.30 56 20 10 mg 0.08 30.33
Cilazapril 17.42 56 5 2.5 mg 0.16 56.81
Zofenopril 13.06 56 30 30 mg 0.23 85.18
Losartan 9.81 56 50 50 mg 0.18 64.00
Valsartan 3.65 28 80 80 mg 0.13 47.55
Irbesartan 6.37 28 150 150 mg 0.23 83.15
Candesartan 5.19 28 8 8 mg 0.19 67.73
Olmesartan 12.41 56 20 20 mg 0.22 80.94
Telmisartan 4.62 56 40 40 mg 0.08 30.13
Amlodipine 5.48 56 5 5 mg 0.10 35.74
Lercanidipine 8.79 56 10 10 mg 0.16 57.33
Verapami 5.37 56 80 240 mg 0.29 105.07
Bisoprolol 3.69 30 10 10 mg 0.12 44.93
Nebivolol 6.15 60 5 5 mg 0.10 37.44
Carvedilol 10.22 56 25 37.5 mg 0.27 99.99
Atenolol 4.44 56 50 75 mg 0.12 43.44
Propranolol 4.86 56 80 160 mg 0.17 63.40
Furosemide 3.63 56 40 40 mg 0.06 23.68
Hydrochlorothiazide 4.88 56 25 25 mg 0.09 31.83
Spironolactone 4.65 56 25 37.5 mg 0.12 45.49
Indapamide 8.73 60 2.5 2.5 mg 0.15 53.14
Chlorthalidone 5.95 60 50 25 mg 0.05 18.11
Aliskiren 19.79 28 150 150 mg 0.71 258.15
Valsartan + Hydrochlorothiazide 8.06 56 80 80 mg 0.14 52.57

Losartan +

Hydrochlorothiazide

7.87 56 50 50 mg 0.14 51.33
Lisinopril + Amlodipine 9.97 56 20 10 mg 0.09 32.51
Lisinopril + Hydrochlorothiazide 11.17 56 20 10 mg 0.10 36.43
Enalapril + Lercanidipine 9.04 56 10 10 mg 0.16 58.96
Amlodipine + Olmesartan 16.05 56 20 20 mg 0.29 104.68
Olmesartan + Hydrochlorothiazide 11.64 56 20 20 mg 0.21 75.92
Amlodipine + Valsartan 16.46 56 5 5 mg 0.29 107.36
Amlodipine + Telmisartan 11.72 28 5 5 mg 0.42 152.88
Telmisartan + Hydrochlorothiazide 7.29 28 40 40 mg 0.26 95.10
Candesartan + Indapamide 8.91 28 8 8 mg 0.32 116.23
Candesartan + Hydrochlorothiazide 7.73 56 16 8 mg 0.07 25.21
Amlodipine + Candesartan 19.52 56 5 5 mg 0.35 127.32
Perindopril + Indapamide 7.32 28 5 4 mg 0.21 76.39
Perindopril + Amlodipine 6.72 28 4 4 mg 0.24 87.66
Ramipril + Hydrochlorothiazide 5.57 56 2.5 2.5 mg 0.10 36.33
Perindopril + indapamide + amlodipine 5.49 56 5 5 mg 0.10 35.81
Amiloride + Hydrochlorothiazide 5.03 56 50 25 mg 0.04 16.40
Irbesartan + Hydrochlorothiazide 5.61 28 150 150 mg 0.20 73.18
Type 2 Diabetes Mellitus
Metformin 3.49 60 1000 2000 mg 0.12 42.49
Sitagliptin 12.55 60 50 100 mg 0.42 152.80
Gliclazide 5.12 56 60 60 mg 0.09 33.39
Vildagliptin 16.95 56 50 100 mg 0.61 221.11
Dulaglutide 53.48 2 500 160 ug 8.56 3 125.37
Empagliflozin 45.40 30 25 17.5 mg 1.06 386.92
Ertugliflozin 39.52 28 15 10 mg 0.94 343.68
Glibenclamide 4.28 60 5 10 mg 0.14 52.11
Linagliptin 48.40 30 5 5 mg 1.61 589.27
Liraglutide 53.58 2 36 1.5 mg 2.23 815.42
Dapagliflozin 42.78 56 10 10 mg 0.76 279.02
Metformin + Vildagliptine 16.75 60 1000 2000 mg 0.56 203.93
Metformin + sitagliptin 16.10 56 1000 2000 mg 0.58 210.02
Metformin + dapagliflozin 44.17 56 1000 2000 mg 1.58 576.18
Metformin + empagliflozin 45.40 56 1000 2000 mg 1.62 592.23
Dyslipidemia
Atorvastatin 6.97 28 20 20 mg 0.25 90.92
Rosuvastatin 9.65 56 20 10 mg 0.09 31.47
Sinvastatin 12.35 56 40 30 mg 0.17 60.41
Pravastatin 13.99 56 40 30 mg 0.19 68.44
Pitavastatin 8.52 56 2 2 mg 0.15 55.57
Ezetemibe 13.59 56 10 10 mg 0.24 88.64
Fenofibrate 5.16 56 200 200 mg 0.09 33.66
Gemfibrozil 9.60 56 600 1200 mg 0.34 125.23
Asthma
Fluticasone 9.97 60 100 200 ug 0.33 121.38
Salmeterol 24.42 60 50 100 ug 0.81 297.31
Formoterol 20.50 60 12 24 ug 0.68 249.59
Salbutamol 3.06 200 100 800 ug 0.12 44.71
Montelukast 34.54 56 10 10 ug 0.62 225.28
Budesonide 18.96 200 200 800 ug 0.38 138.50
Terbutaline 5.79 120 0.5 2 ug 0.19 70.49
Tiotropium bromide 32.26 60 2.5 5 ug 1.08 392.77
Ipatropium bromide 6.50 200 20 120 ug 0.20 71.22
Fluticasone + Salmeterol 16.90 60 50 100 ug 0.56 205.76
Fluticasone + Formoterol 59.16 120 125 200 ug 0.79 288.11
Fluticasone + Vilanterol 39.54 30 184 200 ug 1.43 523.26
Budesonide + Formoterol 36.36 120 160 800 ug 1.52 553.35
Psychiatric Disorder
Fluoxetine 8.76 56 20 20 mg 0.16 57.14
Trazodone 9.15 56 150 300 mg 0.33 119.36
Setraline 5.82 56 50 50 mg 0.10 37.96
Duloxetine 11.06 30 60 60 mg 0.37 134.66
Paroxetine 11.53 56 20 20 mg 0.21 75.20
Fluvoxamine 5.28 56 50 100 mg 0.19 68.88
Escitalopram 9.46 56 10 10 mg 0.17 61.70
Lorazepam 4.70 56 2.5 2.5 mg 0.08 30.65
Bupropiom 17.23 30 300 300 mg 0.57 209.71
Oxazepam 2.40 30 15 50 mg 0.27 97.40
Cloxazolam 6.68 56 0.12 43.57
Bromazepam 3.96 56 3 10 mg 0.24 86.09
Mexazolam 16.14 56 0.29 105.27
Flurazepam 4.32 20 30 30 mg 0.22 78.89
Clonazepam 3.58 56 2 8 mg 0.26 93.40
Diazepam 3.04 56 10 10 mg 0.05 19.83
Loflazepate 5.61 56 2 2 mg 0.10 36.59
Alprazolam 4.10 56 1 1 mg 0.07 26.74
Clorazepate 5.24 56 10 20 mg 0.19 68.35
Quetiapine 15.69 56 100 400 mg 1.12 409.34
Zolpidem 2.94 20 10 10 mg 0.15 53.69
Estazolam 3.71 14 2 3 mg 0.40 145.19
Mirtazapine 9.65 56 30 30 mg 0.17 62.94
Amitriptilyne 3.48 56 10 75 mg 0.47 170.23
Venlafaxine 9.58 30 150 100 mg 0.21 77.76

Prices correspond to the lowest available public selling price in Portugal according to Infarmed

The quantification of the absolute reduction in annual medication costs (in euros) associated with the pharmacological treatment of obesity‑related comorbidities 3 years after MBS was the primary outcome of this study.

In Portugal, prescriptions are issued by active substance, and electronic prescribing records do not allow confirmation of the specific commercial product dispensed, as substitution with generic formulations may occur at the pharmacy level. Therefore, generic pricing was considered when available in this study. Medication prices were defined as the public selling price (PVP) of each medication, obtained from the national medicines pricing database maintained by the Portuguese medicines regulatory authority, INFARMED.

Because data on actual consumption (i.e., number of dispensed packages, dosing regimens) were not available, daily use was assumed to correspond to the Defined Daily Dose (DDD). For each prescribed active substance, the corresponding DDD, representing the assumed average maintenance dose per day for a drug used for its main indication, was obtained from the World Health Organization Collaborating Centre for Drug Statistics Methodology. For each medication, the lowest available price per milligram was considered, using the generic formulation whenever available. In cases where more than one dosage strength existed and the price per milligram differed between strengths, the lowest price per milligram was selected. Thus, the daily cost of medication was calculated by multiplying the price per milligram by the DDD (in milligrams). Finally, the annual cost was obtained by multiplying the estimated daily cost by 365.25 days (i.e., Annual medication cost = DDD Inline graphic cost of a milligram Inline graphic 365.25). The total cost is the result of the sum of the costs of all medications used to treat each comorbidity investigated in this study. The difference between the annual cost at the time of the surgery and the annual cost three years after surgery corresponds to the absolute reduction in annual medication costs. All evaluated medications and corresponding daily and annual prices can be consulted in Table 1.

Furthermore, to assess the magnitude of the reduction in the prevalence and burden of obesity-associated comorbidities, clinical and laboratory data were extracted from SClínico, an electronic medical record platform routinely used within the Portuguese National Health Service.

Clinical data refer to the registered diagnosis of obesity-associated comorbidities before and after surgery, namely type 2 diabetes, hypertension, dyslipidemia, asthma, depressive and anxiety disorders. Blood pressure records were also used.

Laboratory data include lipid profile (LDL and HDL cholesterol and fasting triglycerides), fasting plasma glucose, and glycated hemoglobin (HbA1c).

In the absence of complete medical records, clinical, laboratory and/or pharmacological data were combined to identify some of the obesity-associated comorbidities. Diabetes was defined as use of glucose-lowering medication, a glycated hemoglobin (HbA1c) level ≥ 6.5% or a fasting plasma glucose value ≥ 126 mg/dL. Hypertension was defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg at evaluation or use of antihypertensive medication. Dyslipidemia was defined as LDL cholesterol ≥ 190 mg/dL, HDL cholesterol < 40 mg/dL, fasting triglycerides ≥ 200 mg/dL or current use of lipid-lowering medication. Depressive and anxiety disorders were defined as present if the participant was medicated with antidepressant therapy, with or without concomitant sedative–hypnotic medication. It is important to note that clinical records for psychiatric conditions were frequently incomplete or nonspecific. Therefore, in many cases, diagnoses were inferred based on documented pharmacological treatment rather than explicit diagnostic documentation. Because first-line pharmacological treatments for depression and anxiety substantially overlap, both conditions were grouped into a single category designated as psychiatric disorders.

Postoperative remission of comorbidities was considered when explicitly documented in the medical records. If this information was unavailable, remission was defined by the absence of pharmacological treatment at the 3-year postoperative appointment.

To assess the impact of MBS on obesity-related comorbidities, the prevalence of diabetes, hypertension, dyslipidemia, asthma, and psychiatric disorders was compared at the time of surgery and 3 years later.

To assess the reduction of the burden of the studied comorbidities, an estimate of individual Years Lived with Disability (YLD) was calculated at the time of surgery and at the postoperative assessment. This measure quantifies the non‑fatal burden of disease by weighing each health condition according to its disability severity. Therefore, the disability weight (DW) of each studied comorbidity was obtained from the Global Burden of Disease (GBD) study in order to estimate individual YLD.

In this study, hypertension and dyslipidemia were attributed a DW equal to 0. In addition, with intent of a conservative approach, the DW considered for psychiatric disorders corresponds to mild-anxiety disorders. For each participant, a cumulative disability index was calculated by summing the DW for all diagnosed conditions. For example, an individual with controlled diabetes (DW = 0.0490) and controlled asthma (DW = 0.0146) has an individual YLD of 0.0636. The mean YLD for the sample was then obtained as the arithmetic mean of individual YLD values. It is important to note that this procedure estimates cumulative individual burden rather than population YLD as defined by the GBD, which calculates YLD separately for each condition and uses multiplicative models to account for multimorbidity.

Statistical Analysis

Data analysis was performed using R software (version 4.1.1; R Foundation for Statistical Computing, Vienna, Austria). Continuous variables were described using means and standard deviations (SD), whereas categorical variables were presented as absolute and relative frequencies. To compare means, the normality of the distributions and of paired differences was assessed using the Shapiro–Wilk test, complemented by graphical inspection. When normality assumptions were met, paired t tests were applied; otherwise, non‑parametric methods were used, namely the Wilcoxon signed-rank test or the sign test, depending on the symmetry of the differences. To compare diagnoses before and after surgery, McNemar’s test was applied, which is appropriate for paired dichotomous data.

Results

Participants

A total of 420 patients who underwent MBS between 2018 and 2021 and had a recorded 3-year follow-up appointment were identified. Of these, 37 had undergone revisional surgery and were excluded. The final sample consisted of 383 patients whose medical records were reviewed.

Annual Costs with Medication

In line with the objective of quantifying changes in pharmacotherapy-related healthcare costs 3 years after MBS, pharmacological treatment costs decreased significantly after surgery (p < 0.001), as shown in Table 2. The mean annual reduction was €56.11 per patient. Statistically significant reductions were observed for antihypertensive medications (from €28.39 to €16.32; p < 0.001), lipid-lowering medications (from €17.02 to €12.07; p < 0.001), and antidiabetic medications (from €84.56 to €52.85; p < 0.001). In contrast, reductions in asthma medication costs (€5.76; p = 0.1758) and psychiatric medication costs (€1.62; p = 0.8054) did not reach statistical significance.

Table 2.

Changes in pharmacological costs (€) in the overall sample 3 years after metabolic bariatric surgery

Preoperative Assessment 3 years Postoperative Assessment Difference Wilcoxon test
P-value
Mean SD Mean SD
Total 178.21 557.77 122.09 461.78 -56.11 < 0.001
Hypertension 28.39 48.37 16.32 40.02 -12.08 < 0.001
Dyslipidemia 17.02 35.69 12.07 32.92 -4.95 < 0.001
Type 2 Diabetes 84.56 535.05 52.85 438.77 -31.71 < 0.001
Asthma 17.95 87.63 12.19 83.06 -5.76 0.1758
Psychiatric disorders 30.29 73.45 28.66 65.21 -1.62 0.8054

Prevalence and Burden of Obesity-Associated Comorbidities

Beyond medication costs, the prevalence of obesity-related comorbidities also decreased after MBS. Statistically significant reductions were observed for all studied conditions except psychiatric disorders, whose prevalence was 28% at both assessments (p = 1.000). The prevalence of obesity-related comorbidities before and 3 years after surgery is shown in Fig. 1.

Fig. 1.

Fig. 1

The McNemar test was used to compare paired comorbidities before and after surgery. A statistically significant reduction was observed for asthma (from 8% to 3%), dyslipidemia (from 47% to 15%), type 2 diabetes mellitus (from 26% to 10%) and hypertension (from 41% to 21%), while no significant change was found for psychiatric comorbidities (p = 1)

Finally, changes in disease burden were assessed by comparing mean YLD before surgery and 3 years later. As shown in Table 3, overall disease burden decreased significantly, from a mean YLD of 0.022 before surgery to 0.014 at 3 years (p < 0.001).

Table 3.

Changes in burden of disease in the overall sample 3 years after metabolic bariatric surgery

Preoperative Assessment 3 years postoperative Assessment Difference Paired Wilcoxon
p value
Mean SD Mean SD Mean SD
Total 0.022 0.026 0.014 0.021 -0.008 0.024 < 0.001

Discussion

To our knowledge, this is the first study to evaluate changes in medication-related costs associated with the improvement or remission of obesity-related comorbidities after metabolic bariatric surgery (MBS) in a Portuguese real-world setting. Three years after surgery, MBS was associated with significant reductions in estimated annual pharmacotherapy costs, in the prevalence of several obesity-related comorbidities, and in the estimated burden of disease.

Estimated pharmacological treatment costs decreased by a mean of €56.11 per patient per year. Although modest at the individual level, this reduction has meaningful implications when considered across the large population living with overweight and obesity in Portugal [3]. Moreover, as these reductions are likely to persist over time, their cumulative economic impact progressively increases. Importantly, our study did not analyze the full spectrum of obesity-related diseases or all associated pharmacological treatments. The study included only medications used for the selected comorbidities and did not assess hospital admissions, outpatient consultations, diagnostic tests, work absenteeism, the cost of surgery, or other direct and indirect costs associated with obesity [15]. In addition, generic pricing was used whenever available and costs were estimated from the Defined Daily Dose rather than from actual dispensing or consumption. The reported saving therefore represents a standardized estimate of pharmacotherapy costs within the scope of this study and likely underestimate the broader economic impact of MBS.

Lifelong vitamin and mineral supplementation is also required after MBS and should be considered when interpreting medication-related savings. In Portugal, specialized bariatric multivitamins are not reimbursed by the National Health Service and are paid for by patients, with estimated annual costs ranging from €63.92 to €255.47 in our market survey. Supplements prescribed for specific deficiencies, including iron, vitamin B12, and vitamin D, may be partially reimbursed, although patients may still incur additional costs. Estimated annual costs ranged from €38.78 to €139.25 for oral iron, while maintenance vitamin D and vitamin B12 supplementation cost approximately €11.52 and €38.56 per year, respectively. These expenses were not included in the primary analysis and should be considered alongside the estimated reduction in medications for obesity-related comorbidities.

The reductions in medication costs were consistent with the observed decreases in hypertension, type 2 diabetes mellitus, and dyslipidemia, whose prevalence decreased by 21, 16, and 32% points, respectively. These findings are in line with previous studies documenting improvement in metabolic comorbidities and reduced use of obesity-related medication after MBS [16–18]. Dyslipidemia had the largest absolute reduction in prevalence, from 47% to 15%, but the associated annual medication-cost reduction was only €4.95. This discrepancy may be explained by two factors: (1) Lipid-lowering medications are generally inexpensive; (2) A proportion of patients were diagnosed preoperatively and were not receiving pharmacological treatment before surgery. As such, they did not contribute to reductions in medication costs after surgery.

By contrast, type 2 diabetes mellitus showed the largest reduction in medication costs, reflecting the higher cost of antidiabetic therapy. These cost differences are likely to increase as newer therapies, particularly GLP-1 receptor agonists, become more frequently used, given their substantially higher prices.

The reductions in antihypertensive costs were also consistent with the marked decrease in hypertension prevalence.

No statistically significant change was observed in the prevalence or estimated medication costs of psychiatric disorders. Unlike the metabolic comorbidities evaluated in this study, which are mainly explained by neurophysiological and metabolic mechanisms [19–21], psychiatric disorders have complex biological, psychological, and social determinants that may not respond directly to weight loss [22–24]. This may justify why MBS did not produce a significant effect in the outcomes studied, as it mainly influences biological and psychosocial aspects of depression and anxiety [25]. In fact, even though some studies reported a significant improvement in symptoms of depression and anxiety during the first 12–24 months following surgery [25, 26], other studies reported that no sustained statistically significant differences were observed beyond this period [27, 28]. While some patients experience sustained improvements in mental health, others may present persistence, recurrence, or even worsening of depressive symptoms over time [29]. These heterogeneous trajectories may be influenced by several factors, including psychological resilience, social support, pre-existing eating disorders, and the occurrence of postoperative clinical complications [30, 31]. Furthermore, some studies indicate that postoperative depression may, in certain cases, arise and be associated with new psychosocial stressors that emerge after substantial weight loss, including excess skin, changes in body image perception, increased social scrutiny, or disruptions in interpersonal relationships, rather than relapse of preoperative psychiatric conditions [32]. In this context, the absence of statistically significant differences observed in the present study regarding the prevalence and annual cost reduction of depressive and anxiety disorders may reflect the complex, heterogeneous and time-dependent nature of psychological outcomes after MBS. Interpretation is further limited by the study definition, because psychiatric disorders were frequently inferred from antidepressant treatment rather than from a specific documented diagnosis. Antidepressants may also be prescribed for other indications, including chronic pain and sleep disorders.

Asthma prevalence decreased after MBS, whereas the reduction in estimated asthma-medication costs did not reach statistical significance. This result should be interpreted in light of the study definition of remission, which was based primarily on discontinuation of pharmacological treatment. Previous studies have used different definitions, including symptom-control instruments, spirometry, medication withdrawal, or combinations of these measures. Nevertheless, the reduction in asthma prevalence is consistent with evidence showing decreased use of asthma medication after MBS [33]. The absence of a statistically significant cost reduction may be related to the small number of patients with asthma and the high variability in medication costs.

The estimated mean YLD decreased from 0.022 before surgery to 0.014 at 3 years, supporting a reduction in the cumulative burden associated with the studied comorbidities [34]. However, the disability weights were summed at the individual level to compare health states before and after surgery. This differs from the population-level Global Burden of Disease framework, which estimates YLD separately for each condition and accounts for multimorbidity using multiplicative methods. The values reported here should therefore be interpreted as an individual cumulative disability-burden estimate rather than as formal population YLD. The estimate may also be conservative because depression and anxiety were grouped and only the disability weight attributed to mild anxiety was applied.

This study has additional limitations. Its retrospective, single-center design limits causal inference and generalizability. Diagnoses and decisions to start or discontinue medication were not standardized, and provider- or center-specific treatment practices may have influenced the apparent prevalence and remission of comorbidities. Incomplete clinical records required the combination of diagnostic, laboratory, and pharmacological information. Prescription records were used as a proxy for medication use and do not demonstrate dispensing or adherence. Costs were estimated using DDD values rather than prescribed daily doses, as information on dosing regimens and the number of packages dispensed was unavailable. The study also lacked an untreated control group and did not assess the effect of the surgical procedure, baseline disease severity, postoperative nutritional costs, or the full range of obesity-related conditions.

Despite these limitations, the findings provide real-world Portuguese data on the clinical and pharmacotherapy-related changes observed 3 years after MBS. Future studies should include broader healthcare costs, actual dispensing data, standardized definitions of comorbidity remission, more detailed assessment of psychiatric outcomes, comparisons between surgical procedures, and the costs of surgery and postoperative supplementation.

Conclusion

This study demonstrates that MBS is associated with significant reductions in annual pharmacotherapy costs and disease burden, which may be explained by the remission or improvement of metabolic comorbidities. The stability of antidepressant use highlights the complex and multifactorial nature of mental health after surgery, which may follow a different course from hypertension, dyslipidemia, type 2 diabetes mellitus, and asthma.

In conclusion, although the estimated medication-cost saving per patient was modest, it may have a relevant cumulative impact when considered at the population level and over longer periods.

This study protocol was reviewed and approved by the Institutional Ethics Committee (Ref. CE-443-25; approval date: 21 November 2025). For this type of study, formal informed consent was not required.

Acknowledgements

The authors would like to express their sincere gratitude to all members of the CRIO Group for their valuable contributions to this work.

Author Contributions

A.O. contributed to the acquisition, analysis and interpretation of the patient data and was a major contributor in writing the manuscript. C.B., P.A. and M.B. contributed to the analysis and interpretation of the patient data and also in writing the manuscript. E.L.C., H.S.S. and P.F. drafted the work and substantively revised it. All the authors read and approved the final manuscript.

Funding

This study was not supported by any sponsor or funder.

Data Availability

There is a restriction applied to the data that support the findings of this study; therefore, the data are not publicly available. Data are, however, available from the authors upon reasonable request. Contact the corresponding author.

Declarations

Ethics

This study protocol was reviewed and approved by the Institutional Ethics Committee (Ref. CE-443-25; approval date: 21 November 2025). For this type of study, formal informed consent was not required.

Competing interests

The authors declare: A.O. is affiliated with the Faculty of Medicine, University of Porto. C.B., P.A. and M.B. are employees of IQVIA Portugal. M.B. is also a member of the Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa. H.S. and E.L.C. are affiliated with the Integrated Responsibility Center for Obesity, São João Local Health Unit, Porto, and the Faculty of Medicine, University of Porto. P.F. is affiliated with the Integrated Responsibility Center for Obesity, São João Local Health Unit, Porto, the Department of Medicine, Faculty of Medicine, University of Porto, and the I3S – Institute for Research and Innovation in Health, University of Porto. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.World Health Organization [Internet]. Geneva: Obesity and overweight fact sheet [cited 2026 Feb 27]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
  • 2.Omer TA. The causes of obesity: an in-depth review. Adv Obes Weight Manag Control. 2020;10(4):90–4. 10.15406/aowmc.2020.10.00312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.World Health Organization [Internet]. Portugal: country overview [cited 2026 Feb 27]. Available from: https://data.who.int/countries/620.
  • 4.De Lorenzo A, Gratteri S, Gualtieri P, Cammarano A, Bertucci P, Di Renzo L. Why primary obesity is a disease? J Transl Med. 2019;17(1):169. 10.1186/s12967-019-1919-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism. 2019;92:121–35. 10.1016/j.metabol.2018.11.001. [DOI] [PubMed] [Google Scholar]
  • 6.De Luca M, Shikora S, Eisenberg D, Angrisani L, Parmar C, Alqahtani A, et al. Scientific Evidence for the Updated Guidelines on Indications for Metabolic and Bariatric Surgery (IFSO/ASMBS). Obes Surg. 2024;34(11):3963–4096. 10.1007/s11695-024-07370-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, Billington CJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013;309(21):2240–9. 10.1001/jama.2013.5835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Apovian CM, Aronne L, Barenbaum SR, editors. Clinical management of obesity. 3rd ed. West Islip (NY): Professional Communications Inc.; 2025. [Google Scholar]
  • 9.Law S, Dong S, Zhou F, Zheng D, Wang C, Dong Z. Bariatric surgery and mental health outcomes: an umbrella review. Front Endocrinol (Lausanne). 2023;14:1283621. 10.3389/fendo.2023.1283621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Forno E, Celedón JC. The effect of obesity, weight gain, and weight loss on asthma inception and control. Curr Opin Allergy Clin Immunol. 2017;17(2):123–30. 10.1097/ACI.0000000000000339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Dixon JB, Chapman L, O’Brien P. Marked improvement in asthma after Lap-Band surgery for morbid obesity. Obes Surg. 1999;9(4):385–9. 10.1381/096089299765552981. [DOI] [PubMed] [Google Scholar]
  • 12.Dixon AE, Pratley RE, Forgione PM, Kaminsky DA, Whittaker-Leclair LA, Griffes LA, et al. Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J Allergy Clin Immunol. 2011;128(3):508–15. . . 10.1016/j.jaci.2011.06.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Welbourn R, Hollyman M, Kinsman R, Dixon J, Liem R, Ottosson J, et al. Bariatric surgery worldwide: baseline demographic description and one-year outcomes from the fourth ifso global registry report 2018. Obes Surg. 2019;29(3):782–95. 10.1007/s11695-018-3593-1. [DOI] [PubMed] [Google Scholar]
  • 14.Angrisani L, Santonicola A, Iovino P, Palma R, Kow L, Prager G, et al. IFSO Worldwide Survey 2020–2021: Current Trends for Bariatric and Metabolic Procedures. Obes Surg. 2024;34(4):1075–85. 10.1007/s11695-024-07118-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Borges M, Sampaio F, Costa J, Freitas P, Matias Dias C, Gaio V, et al. Burden of Disease and Cost of Illness of Overweight and Obesity in Portugal. Obes Facts. 2025;18(2):107–20. 10.1159/000541781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Courcoulas AP, King WC, Belle SH, Berk P, Flum DR, Garcia L, et al. Seven-Year Weight Trajectories and Health Outcomes in the Longitudinal Assessment of Bariatric Surgery (LABS) Study. JAMA Surg. 2018;153(5):427–34. 10.1001/jamasurg.2017.5025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Peterli R, Wölnerhanssen BK, Peters T, Vetter D, Kröll D, Borbély Y, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial. JAMA. 2018;319(3):255–65. 10.1001/jama.2017.20897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Kauppila JH, Markar S, Santoni G, Holmberg D, Lagergren J. Temporal Changes in Obesity-Related Medication After Bariatric Surgery vs No Surgery for Obesity. JAMA Surg. 2023;158(8):817–23. 10.1001/jamasurg.2023.0252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Batterham RL, Cummings DE. Mechanisms of Diabetes Improvement Following Bariatric/Metabolic Surgery. Diabetes Care. 2016;39(6):893–901. 10.2337/dc16-0145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Samson R, Ayinapudi K, Le Jemtel TH, Oparil S. Obesity, Hypertension, and Bariatric Surgery. Curr Hypertens Rep. 2020;22(7):46. 10.1007/s11906-020-01049-x. [DOI] [PubMed] [Google Scholar]
  • 21.Heffron SP, Parikh A, Volodarskiy A, Ren-Fielding C, Schwartzbard A, Nicholson J. all. Changes in Lipid Profile of Obese Patients Following Contemporary Bariatric Surgery: A Meta-Analysis. Am J Med. 2016;129(9):952–9. 10.1016/j.amjmed.2016.02.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Qi X, Yang J, Liu L, Hao J, Pan C, Wen Y, et al Socioeconomic inequalities, genetic susceptibility, and risks of depression and anxiety: A large-observational study. J Affect Disord. 2024;367:174–83. 10.1016/j.jad.2024.09.009. [DOI] [PubMed] [Google Scholar]
  • 23.Ohi K, Otowa T, Shimada M, Sasaki T, Tanii H. Shared genetic etiology between anxiety disorders and psychiatric and related intermediate phenotypes. Psychol Med. 2020;50(4):692–704. 10.1017/S003329171900059X. [DOI] [PubMed] [Google Scholar]
  • 24.Struijs SY, de Jong PJ, van der Jeronimus BF, Riese H, Spinhoven P. Psychological risk factors and the course of depression and anxiety disorders: A review of 15 years NESDA research. J Affect Disord. 2021;295:1347–59. 10.1016/j.jad.2021.08.086. [DOI] [PubMed] [Google Scholar]
  • 25.Loh HH, Francis B, Lim LL, Lim QH, Yee A, Loh HS. Improvement in mood symptoms after post-bariatric surgery among people with obesity: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2021;37(8):e3458. 10.1002/dmrr.3458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Gill H, Kang S, Lee Y, Rosenblat JD, Brietzke E, Zuckerman H, et al. The long-term effect of bariatric surgery on depression and anxiety. J Affect Disord. 2019;246:886–94. . 10.1016/j.jad.2018.12.113. [DOI] [PubMed] [Google Scholar]
  • 27.Dawes AJ, Maggard-Gibbons M, Maher AR, Booth MJ, Miake-Lye I, Beroes JM, et al. Mental Health Conditions Among Patients Seeking and Undergoing Bariatric Surgery: A Meta-analysis. JAMA. 2016;315(2):150–63. 10.1001/jama.2015.18118. [DOI] [PubMed] [Google Scholar]
  • 28.Mitchell JE, King WC, Chen JY, Devlin MJ, Flum D, Garcia L et al. Course of depressive symptoms and treatment in the longitudinal assessment of bariatric surgery (LABS-2) study. Obes (Silver Spring). 2014;22(8):1799–806. . 10.1002/oby.20738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Budin AJ, Brown WA, MacCormick AD, Caterson I, Sumithran P. Depressive symptoms at short-, medium-, and long-term follow-up after bariatric surgical procedures: A systematic review and meta-analysis. Obes Rev. 2025;26(8):e13927. 10.1111/obr.13927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.McGarrity LA, Terrill AL, Martinez PL, Ibele AR, Morrow EH, Volckmann ET, Smith TW. The Role of Resilience in Psychological Health Among Bariatric Surgery Patients. Obes Surg. 2022;32(3):792–800. 10.1007/s11695-021-05855-3. [DOI] [PubMed] [Google Scholar]
  • 31.Pyykkö JE, van Olst N, Gerdes VEA, Almansa J, Acherman YIZ, De Brauw M, et al. Relations between trajectories of weight loss and changes in psychological health over a period of 2 years following bariatric metabolic surgery. Qual Life Res. 2025;34(5):1345–61. . 10.1007/s11136-025-03906-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Lyons K, Meisner BA, Sockalingam S, Cassin SE. Body image after bariatric surgery: a qualitative study. Bariatr Surg Pract Patient Care. 2014;9(1):41–9. 10.1089/bari.2014.0001. [DOI] [Google Scholar]
  • 33.Xie L, Chandrasekhar A, DeSantis SM, Almandoz JP, de la Cruz-Muñoz N, Messiah SE. Discontinuation and reduction of asthma medications after metabolic and bariatric surgery: A systematic review and meta-analysis. Obes Rev. 2023;24(2):e13527. 10.1111/obr.13527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Simonson DC, Gourash WF, Arterburn DE, Hu B, Kashyap SR, Cummings DE, et al. Health-Related Quality of Life and Health Utility After Metabolic/Bariatric Surgery Versus Medical/Lifestyle Intervention in Individuals With Type 2 Diabetes and Obesity: The ARMMS-T2D Study. Diabetes Care. 2025;48(4):537–45. 10.2337/dc24-2046. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

There is a restriction applied to the data that support the findings of this study; therefore, the data are not publicly available. Data are, however, available from the authors upon reasonable request. Contact the corresponding author.


Articles from Obesity Surgery are provided here courtesy of Springer

RESOURCES